Monday, March 04, 2024 9:45:46 AM
================
Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver Meeting
Feb 29, 2024
https://www.morningstar.com/news/globe-newswire/9055645/ocean-biomedical-nasdaq-ocea-announces-joint-venture-partner-virion-therapeutics-to-present-their-first-clinical-study-data-as-an-accepted-late-breaker-presentation-at-2024-apasl-global-liver-meeting
================
About Virion Therapeutics:
At Virion Therapeutics, We Believe a Future Free of Cancer and Chronic Infectious Diseases Is Within Reach
https://www.viriontx.com/about/#
================
Chirinjeev Kathuria, M.D., MBA
Executive Committee (Virion Therapeutics)
Dr. Chirinjeev Kathuria is an Indian-American investor, physician, politician, businessperson, and philanthropist. He is the Chairman and Co-founder of Ocean Biomedical – a NASDAQ-listed biopharmaceutical company that is pursuing programs in oncology, fibrosis, infectious disease, and inflammation.
Dr. Kathuria has founded and served as Chairman on several publicly listed companies, including the AIRO Group, which brings together technologies and services in urban air mobility, commercial and military aviation, and avionics. He also co-founded a leading global digital healthcare company – American Teleradiology NightHawks, Inc., which merged with NightHawk Radiology Holdings, Inc., and the combined company went public on NASDAQ. Dr. Kathuria also co-founded UpHealth a leading global digital healthcare company that went public on NYSE.
Dr. Kathuria has been involved in space exploration and was the Founding Director of MirCorp; the first commercial company to privately launch and fund manned space programs.
Dr. Kathuria ran for U.S. senate in Illinois becoming the first Indian-American to run for the US Senate in US history, in a race that included eventual winner, President Barack Obama.
Dr. Kathuria received a Bachelor of Science degree and Doctorate of Medicine from Brown University and a Master of Business Administration from Stanford University.
https://www.viriontx.com/team/chirinjeev-kathuria/
$OCEA
Don't invest what you can't afford to lose. Always do your own DD. INV4$
Recent OCEA News
- Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Annual Report on Form 10-K • GlobeNewswire Inc. • 04/24/2024 08:51:06 PM
- Ocean Biomedical (NASDAQ: OCEA) Congratulates JV Partner, Virion Therapeutics, on Promising First-Ever Human Phase 1B Clinical Safety Data for Their Lead Checkpoint Modifier-Containing Immunotherapy for HBV Functional Cure, at Global APASL • GlobeNewswire Inc. • 03/28/2024 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/08/2024 10:00:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/04/2024 10:22:43 PM
- Ocean Biomedical (NASDAQ: OCEA) Announces Joint Venture Partner, Virion Therapeutics to Present Their First Clinical Study Data as an Accepted Late Breaker Presentation at 2024 APASL Global Liver Meeting • GlobeNewswire Inc. • 02/29/2024 01:01:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/13/2024 11:43:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 10:05:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/17/2024 09:05:30 PM
- Ocean Biomedical, Inc. Announces Publication of Groundbreaking Breast Cancer Research Uncovering a New Tumor Suppression Pathway for Its Proprietary Anti-Chi3L1 Antibody • GlobeNewswire Inc. • 12/05/2023 01:15:00 PM
- Ocean Biomedical, Inc. Announces Receipt of Notice from Nasdaq Regarding Late Filing of Quarterly Report on Form 10-Q • GlobeNewswire Inc. • 11/29/2023 10:41:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/15/2023 11:20:11 AM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 11/15/2023 11:20:04 AM
- Ocean Biomedical (NASDAQ: OCEA) Announces Positive Preclinical Oncology Data for VRON-0300, Presented at SITC 2023 Annual Meeting, and Clinical Updates by 50/50 Joint Venture Partner Virion Therapeutics • GlobeNewswire Inc. • 11/14/2023 01:01:00 PM
- Ocean Biomedical (NASDAQ: OCEA) Announces First Patients Dosed by Joint Venture Partner Virion Therapeutics in Phase 1b Study of Novel Immunotherapy for Chronic Hepatitis B Virus Infection • GlobeNewswire Inc. • 10/26/2023 09:30:00 AM
- Virion Therapeutics and Joint Venture Partner, Ocean Biomedical (NASDAQ: OCEA), Announce First Patients Dosed with Novel Immunotherapy Evaluating a Functional Cure for Chronic Hepatitis B Virus Infection • PR Newswire (US) • 10/26/2023 09:30:00 AM
- Ocean Biomedical (NASDAQ: OCEA) Announces $1 Million Falk Award for Malaria Drug Candidate Addressing Evolving Resistance to Artemisinin-Based Therapeutics to Chief Scientist Dr. Jonathan Kurtis • GlobeNewswire Inc. • 10/24/2023 10:30:00 AM
- Ocean Biomedical (NASDAQ: OCEA) Announces Enrollment of Patients for Phase 1b Study for Chronic Hepatitis B Treatment in 50-50 Joint Venture with Virion Therapeutics • GlobeNewswire Inc. • 10/17/2023 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/12/2023 09:10:17 PM
- Virion Therapeutics and Ocean Biomedical form joint venture supporting multi-national, first-in-humans clinical chronic hepatitis B study: now enrolling, with goal of a functional cure for a disease affecting 300+ million patients worldwide • PR Newswire (US) • 10/12/2023 12:01:00 PM
- Ocean Biomedical and Virion Therapeutics Form Joint Venture Supporting Multi-National, First-In-Humans Clinical Chronic Hepatitis B Study: Now Enrolling, With Goal of a Functional Cure for a Disease Affecting 300+ Million Patients Worldwide • GlobeNewswire Inc. • 10/12/2023 12:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2023 09:25:20 PM
- Updated: Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with Polar Multi-Strategy Master Fund • GlobeNewswire Inc. • 10/04/2023 08:56:00 PM
- Ocean Biomedical Announces Loan Commitment from Largest Stockholder; Up to $10 Million • GlobeNewswire Inc. • 10/04/2023 12:01:00 PM
- Ocean Biomedical Announces Non-Dilutive Amendment to Existing Agreement with a Key Financing Partner • GlobeNewswire Inc. • 10/03/2023 06:30:00 PM
- Ocean Biomedical Announces Newly Published Findings Demonstrating Ability to Restore Treatment Sensitivity to AstraZeneca’s Leading Lung Cancer Drug After Resistance Has Formed, and Enhanced Tumor Suppression in EGFR-Mutation Lung Cancers • GlobeNewswire Inc. • 10/03/2023 12:01:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM